Compare Fortinet Inc (FTNT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs BIO-TECHNE Corp — how do they compare? Fortinet Inc trades at $161.55 (market cap $120.48B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: Fortinet Inc is far larger — about 10.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals.
| FTNT | TECH | |
|---|---|---|
Market Cap | $120.48B | $11.24B |
Sector | Technology | Health |
52-Week High | $168.29 | $72.29 |
52-Week Low | $74.57 | $43.31 |
Enterprise Value | $116.91B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $159.64, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus price target of $174.50. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.90 surpassing the $0.746 expectation. Revenue growth remains robust, climbing to $6.80 billion in 2025, while net income margins exceed 28%. Positive media coverage highlights strong AI-driven cybersecurity demand and platform expansion.
Outlook is favorable given earnings momentum and industry tailwinds, but high valuation ratios (P/E of 56.41) pose a risk if growth slows. Investor sentiment is supported by analyst buy ratings (42.65%) and institutional accumulation, though competitive pressures and macroeconomic volatility require monitoring.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
